Introduction {#Sec1}
============

The four mammalian members of the protease-activated receptor (PAR) family PAR1, PAR2, PAR3, and PAR4 are encoded by the genes F2R \[[@CR1]\], F2RL1 \[[@CR2]\], F2RL2 \[[@CR3]\], and F2RL3 \[[@CR4]\], respectively. Human PAR1 was discovered in 1991 as a key thrombin receptor on platelets \[[@CR5], [@CR6]\]. Although human and mouse PAR2 genes are homologous to PAR1 genes, PAR2 is not responsive to thrombin \[[@CR2], [@CR7], [@CR8]\]. Unexpected responses of platelets to thrombin in PAR1 knockout mice lead to the discovery of the thrombin receptors PAR3 and PAR4 \[[@CR4], [@CR9], [@CR10]\]. PAR regulation varies between species and tissues, with differing expression levels, protease cleaving activities, dimerization with other receptors, compartimentalization, trafficking, posttranslational modifications, and co-localization with co-receptors, as shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Mechanisms of PAR activation. PAR activation is regulated by **a** direct proteolytic cleavage at the N-terminus, **b** homo- or heterodimerization with other PARs and transactivation through the cleaved tethered ligand, **c** compartmentalization on the cell surface, **d** degradation or recycling by endosomal trafficking, **e** posttranslational modifications such as glycosylation, phosphorylation, and ubiquitination, and **f** co-localization with other receptors and cofactors

Studies of PAR activation under physiological conditions are crucial for the understanding of the pathophysiological roles of PARs, such as those in inflammatory disorders.

Cleavage and activation of PARs and signal transduction {#Sec2}
=======================================================

PARs are specifically cleaved and irreversibly activated by various endogenous proteases, and by exogenous proteases from bacteria, plants, fungi, and insects. Proteases, soluble or cell membrane associated (bound to co-receptors or specific membrane compartments), cleave specific N-terminal peptides of PARs, resulting in exposure of new N-terminal peptides that serve as tethered activation ligands, which bind a conserved region on extracellular loop 2 (ECL2) \[[@CR5], [@CR11]\]. This interaction initiates conformational changes and alters affinity for intracellular G proteins \[[@CR12]\]. Various N-terminal cleavage sites have been described, and these have various active conformations with specific G protein preferences. Multiple cleavage site-specific cellular responses are generally referred to as biased signaling, and the ensuing models describe how distinct proteases with distinct cleavage sites induce protease-specific responses via the same PAR \[[@CR13], [@CR14]\].

In contrast with PAR-activating proteases, other proteases cleave PARs at cleavage sites that are not related to signaling. Under these conditions, shedding of the PAR1 terminus, which removes the thrombin activation site, was first recognized as a mechanism for rendering platelets irresponsive to thrombin \[[@CR15]\]. These truncated PARs can no longer be proteolyticaly activated, but remain activated by ligands from adjacent PARs \[[@CR16]\]. Alternatively, truncated PARs bind soluble peptides with affinity for ECL2 by mimicking the tethered ligand. Both mechanisms result in receptor activation \[[@CR17], [@CR18]\]. Multiple ECL2-binding agonist peptides have been described and shown to induce signaling from truncated and uncleaved PARs (see agonist peptides in Tables [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}).

PAR activation by proteolytical cleavage {#Sec3}
----------------------------------------

PAR-cleaving proteases are a focus of many current studies. Whereas some PAR-cleaving proteases produce N-terminal components with regulatory roles, others render the receptors irresponsive to further protease exposure as shown in Fig. [2](#Fig2){ref-type="fig"} and summarized in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. Important proteases are discussed below.Fig. 2Proteolytic PAR cleavage. **a** N-terminal sequences of human PARs (PAR1--4) containing potential cleavage sites. **b** Proteolytic cleavage of PARs by soluble exogenous proteases exposes new N-terminal sequences that serve as tethered ligands for G protein dependent activation of receptors. Alternatively, proteolytic cleavage at other sites destroys the function of the receptor to prevent intracellular signal transductionTable 1PAR1 cleaving proteasesProteaseMajor cleavage siteAdditional cleavage sitesMammalian proteasesThrombinR^41^S^42^aPCR^46^N^47^R^41^S^42^FVIIaunknownFXaR^41^S^42^TrypsinR^41^S^42^ChymaseunknownMMP-1D^39^P^40^, L^44^L^45^, F^87^I^88^N^47^P^48^, R^70^L^71^,K^82^Q^83^MMP-2L^38^D^39^MMP-3,-8,-9R^41^S^42^MMP-12unknownMMP-13S^42^F^43^L^38^T^39^, mouseCathepsin GR^41^S^42^, F^55^W^56^, Y^69^R^70^Neutrophil elastaseA^36^T^37^, V^72^S^73^, A^86^F^87^Proteinase-3A^36^T^37^, P^48^N^49^, V^72^S^73^, A^92^S^93^PlasminK^32^A^33^, R^41^S^42^, R^70^ L^71^, K^76^ S^77^, K^82^ Q^83^Kallikrein-4,-5,-6unknownKallikrein-14R^46^N^47^Granzyme A,B, KunknownCalpain-1K^32^A^33^, S^76^K^77^Non-mammalian proteasesPA-BJR^41^S^42^, R^46^N^47^ThrombocytinR^41^S^42^, R^46^N^47^DerP1unknownGingipain RR^41^S^42^SpeBL^44^L^45^LepAunknown*S.pneumoniae* proteasesunknownThermolysinF^43^L^44^, L^44^L^45^penCR^41^S^42^Table 2PAR2 cleaving proteasesProteaseMajor cleavage siteAdditional cleavage sitesMammalian proteasesThrombinR^36^S^37^aPCunknownFXaR^36^S^37^TrypsinR^36^S^37^K^34^G^35^, K^51^G^52^, K^72^L^73^TryptaseR^36^S^37^ChymaseG^35^R^36^L^38^I^39^, mouseMatriptaseR^36^S^37^Cathepsin GF^65^S^66^F^59^S^60^, F^64^S^65^Cathepsin SG^40^K^41^E^56^P^57^, mouseNeutrophil elastaseA^66^S^67^, S^67^V^68^V^42^D^43^,V^48^T^49^,V^53^T^54^,V^58^T^59^,T^74^T^75^,V^76^F^77^Proteinase-3D^62^E^63^V^48^T^49^,V^55^E^56^,T^57^V^58^ V^61^D^62^,K^72^L^73^,T^74^T^75^,T^75^V^76^,V^76^F^77^PlasminR^36^S^37^K^34^G^35^TestisinunknownKallikrein-4,unknownKallikrein-5,-6,-14R^36^S^37^Calpain-2unknownNon-mammalian proteasesDer-P1,-P2,-P3,-P9unknownCockroach E1-E3R^36^S^37^Gingipain RunknownLepAunknownEPaS^37^L^38^S^38^L^39^, rat*S.pneumoniae* proteasesunknownThermolysinunknownSerralysinunknown*P.acnes* proteasesunknownaPAunknownBromelainunknownFicinunknownPapainunknownpenCR^36^S^37^Table 3PAR3 cleaving proteasesProteaseMajor cleavage siteAdditional cleavage sitesMammalian proteasesThrombinK^38^T^39^mouse PAR3 at K^37^S^38^aPCR^41^G^42^FXaR^41^G^42^TrypsinunknownTable 4PAR4 cleaving proteasesProteaseMajor cleavage siteAdditional cleavage sitesMammalian proteasesThrombinR^47^G^48^TrypsinR^47^G^48^Cathepsin GR^47^G^48^Kallikrein-14unknownNon-mammalian proteasesPA-BJR^47^G^48^ThrombocytinR^47^G^48^Der-P3unknownGingipain RR^47^G^48^LepAunknown*S.pneumoniae* proteasesunknownBromelainunknownFicinunknownPapainunknown

### Mammalian proteases {#Sec4}

#### Serine proteases {#FPar1}

Thrombin, the key protease of coagulation, is generated by proteolytic cleavage of zymogen prothrombin. Although thrombin production predominantly occurs on platelets and subendothelial vascular walls, extravascular thrombin has been detected in synovial fluid \[[@CR19]\] and around tumors \[[@CR20]\]. Thrombin has long been known to activate platelets, and the discovery of PAR1 initiated research into the underlying molecular mechanisms. PAR1 contains a hirudin-like domain, which has a high affinity thrombin binding site and recruits thrombin via exosite I. This interaction enables thrombin to specifically and efficiently activate PAR1 \[[@CR6]\]. Similarly, PAR3 contains a hirudin-like thrombin recruitment site, which results in cleavage \[[@CR9], [@CR21]\]. In other studies, mouse PAR3 maintained thrombin recruitment activity but lost its receptor function, as discussed above \[[@CR22]--[@CR24]\]. Thrombin also cleaves and activates PAR4, which, in contrast with PAR1, lacks a hirudin-like domain. Thus, higher concentrations of thrombin activate PAR4 and initiate intracellular signaling \[[@CR10]\]. PAR2 is considered the only PAR that resists cleavage or activation by thrombin \[[@CR4], [@CR25]\], although emerging evidence suggests that at very high concentrations (100--500 nM), thrombin may directly cleave and activate PAR2 \[[@CR26], [@CR27]\].

In contrast with thrombin, the anticoagulant protease activated protein C (aPC) binds to the co-receptor endothelial protein C receptor (EPCR) to promote the cleavage and activation of co-localized PAR1 \[[@CR28], [@CR29]\] and induce anti-apoptotic and protective effects on endothelial barrier permeability \[[@CR29]--[@CR33]\]. Compartmentalization of PAR1 and co-localization with EPCR in calveolae is crucial for efficient cleavage by aPC \[[@CR13]\]. Moreover, aPC cleaves PAR3 in humans and mice \[[@CR21], [@CR34], [@CR35]\] and acts as a PAR3 shedding protease that prevents thrombin-induced barrier disruption \[[@CR21]\]. However, the dependency of aPC cleavage of PAR3 on EPCR remains controversial \[[@CR21], [@CR35]\]. Similar to aPC, coagulation factor Xa binds EPCR and mediates proteolytic activation of PAR1 and PAR3 \[[@CR21], [@CR28], [@CR36]--[@CR39]\]. In addition, EPCR-bound factor Xa reportedly cleaves PAR2 and initiates inflammatory signaling \[[@CR40]\]. PAR2 was also shown to be activated by tissue factor (TF)-bound coagulation factor VIIa \[[@CR40]--[@CR42]\]. Yet recent studies suggest that the TF-VIIa complex does not directly activate PAR2, and rather activates matriptase, which cleaves and activates PAR2 \[[@CR42]--[@CR44]\]. Anti-inflammatory signaling was also previously related to PAR1 cleavage by EPCR-bound VIIa \[[@CR45], [@CR46]\]. Taken together, these studies indicate that TF-Xa--VIIa complexes activate PAR1 and PAR2 \[[@CR47]\].

Trypsins are PAR-activating proteases with roles as major digestive enzymes in the duodenum \[[@CR48]\]. Trypsin is also secreted by epithelial cells, nervous system cells \[[@CR49]\], and tumor cells \[[@CR50], [@CR51]\]. Trypsins may also be involved in cell growth and coagulation, as suggested by secretion from human vascular endothelial cells \[[@CR52]\]. Trypsin cleaves human PAR1 and PAR4 at putative protease cleavage sites, and thereby prevents thrombin signaling in endothelial cells and platelets \[[@CR4], [@CR53]\]. Trypsin is the major PAR2 cleaving protease that initiates inflammatory signaling \[[@CR2], [@CR7]\].

Tryptase is the main protease of mast cells, and activates PAR2 by proteolytic cleavage to induce calcium signaling and proliferation \[[@CR54]--[@CR57]\]. The source tissue of tryptase reportedly plays an important role in the cleavage and induction of tryptase-activated PAR signaling, reflecting differences in posttranslational modifications, such as glycosylation and sialic acid modifications \[[@CR54], [@CR58]\]. Tryptase induces calcium signaling via PAR1 when PAR2 is co-expressed, but cannot activate human platelets, suggesting that tryptase does not directly cleave PAR1 \[[@CR54]--[@CR57]\]. Chymase is a mast cell serine protease that also cleaves PAR1 in human keratinocytes and fibroblasts, and thus prevents thrombin sensitivity \[[@CR59]\]. Moreover, the epithelial serine protease matriptase cleaves and initiates inflammatory responses in human and mouse keratinocytes and in *Xenopus* oocytes overexpressing human PAR2 \[[@CR44], [@CR60]--[@CR63]\].

PARs have been identified as substrates of kallikreins, which are serine proteases that have been related to various inflammatory and tumorigenic processes \[[@CR64]\]. Kallikrein-4 increases intracellular calcium levels via PAR1 and PAR2, but activates PAR1 most efficiently \[[@CR65]\]. Kallikrein-14 induces calcium signaling via PAR1, PAR2, and PAR4, but can also shed PAR1 to prevent signaling. Rat platelets are activated by kallikrein-14 via the proteolytic cleavage of PAR4, but are not activated by kallikrein-5 and kallikrein-6 \[[@CR66]\]. Instead, neurotoxic effects of kallikrein-6 were inhibited by blocking PAR1 and PAR2, indicating a direct proteolytic role in PAR activation \[[@CR67]\].

Neutrophils are mobilized to sites of inflammation and infection, where they modulate inflammatory signaling, in part by secreting PAR-cleaving proteases. The neutrophil serine protease cathepsin G prevents thrombin-induced effects by cleaving PAR1 into non-functional parts \[[@CR68], [@CR69]\]. In contrast, cathepsin G reportedly induced chemoattractant signaling via PAR1, further supporting the role of cathepsin G in PAR1 activation \[[@CR70]\]. Another unexpected observation of cathepsin G was that cleavage sites differ between recombinant and native human PAR2 \[[@CR26], [@CR71], [@CR72]\]. These discrepancies may reflect the influence of cell types and posttranslational modifications on PAR cleavage. Studies in mice and humans show that platelet activation by cathepsin G is dependent on PAR3 and PAR4 \[[@CR71], [@CR73], [@CR74]\]. Cathepsin G also cleaves and activates PAR4 on endothelial cells \[[@CR75]\]. The neutrophil proteases elastase and proteinase-3 cleave recombinant PAR1 and PAR2 at various sites \[[@CR26], [@CR72]\]. Recently, rat elastase was shown to cleave and activate PAR1, although sequences of rat and human PAR1 have low homology \[[@CR76]\]. In contradiction with neutrophil proteases that prevent PAR signaling at sites of inflammation, monocytes secret the protease cathepsin S, which initiates inflammatory signaling by cleaving PAR2 \[[@CR72], [@CR77], [@CR78]\]. Low concentrations of the fibrinolytic protease plasmin prevent platelet activation by cleaving PAR1, whereas high concentrations of plasmin lead to the cleavage and activation of PAR1 \[[@CR79]\]. Plasmin also cleaves PAR2 and prevents subsequent activation by trypsin \[[@CR26], [@CR80]\].

The serine proteases granzyme A and granzyme B induce intracellular signaling pathways that lead to neuronal death via PAR1 \[[@CR81], [@CR82]\]. Recently, granzyme K was also shown to activate PAR1 and promote inflammatory endothelial signaling \[[@CR83], [@CR84]\]. Few studies show activation of PAR1 by proteases of the granzyme family, and the details of this interaction remain poorly characterized.

#### Cysteine proteases {#FPar2}

Calpain-1 is a calcium-dependent cysteine protease that has been associated with inflammatory disorders, and initiates calcium signaling pathways by activating PAR1 \[[@CR26]\]. At very high concentrations, calpain-2 was also shown to cleave PAR2, and the authors suggested that this cleavage event inactivated PAR2 \[[@CR26]\]. Recently, calpain-1 was shown to be induced by thrombin-activated PAR1, and subsequently regulated the internalization of PAR1 \[[@CR85]\].

#### Metalloproteases {#FPar3}

Matrix metalloproteases (MMPs) are known to be involved in various inflammatory- and cancer-related conditions. MMP-1 cleaves human PAR1 and initiates platelet activation \[[@CR86]--[@CR89]\]. MMP-1 also regulates cancer cell activities depending on PAR1 availability \[[@CR90]\]. Similarly, MMP-2 cleaves human PAR1 and enhances platelet activation \[[@CR91]\], and MMP-3, MMP-8, and MMP-9 were shown to induce platelet activation via PAR1 \[[@CR92]\]. Whether these three MMPs cleave PAR2 is not clear, although PAR2 activation by trypsin induced secretion of MMP-9 in human airways, suggesting that MMP-9 is a PAR2-activating protease \[[@CR93]\]. In mice, PAR1 expression was regulated by MMP-12, and activated PAR1 increased MMP-12 secretion \[[@CR94], [@CR95]\]. A similar feedback loop involving MMP-12 and PAR2 has been reported in mice \[[@CR96]\]. Moreover, MMP-13 was shown to activate PAR1 and induce intracellular signaling \[[@CR87]\], and thrombin-induced activation of PAR1 and PAR3 was associated with increased levels of MMP-13 in human chondrocytes \[[@CR24]\].

In addition to coagulation and inflammation, PAR activation may play roles in human germ cells, where the serine protease testisin activates PAR2 and induces calcium signaling and ERK1/2 activation. This interaction may play roles in the regulation of ovarian and testicular cancer, as suggested previously \[[@CR97], [@CR98]\].

### Non-mammalian proteases {#Sec5}

Exogenous proteases from various species that modulate PAR activation are disscues in the following section and are summarized in Fig. [3](#Fig3){ref-type="fig"}.Fig. 3Non-mammalian exogenous proteases induce PAR-driven pathological effects. Various proteases are secreted from bacteria, amoebae, insects, plants, fungi, and snakes, and can cleave PARs and modulate signal transduction, leading to inflammation, thrombosis, or pain

#### Bacterial proteases {#FPar4}

Endogenous mammalian proteases are not the only regulators of PAR activation. Indeed, both pathogenic and commensal bacteria secret various proteases that cleave PARs and act as inflammatory modulators \[[@CR99]\]. In this section, we describe bacterial proteases that either activate PARs, and thus allow bacteria to penetrate host barriers, or inactivate PARs to prevent inflammatory signaling by the host.

The human pathogen *Pseudomonas aeruginosa* secrets two PAR-cleaving proteases with contrasting effects. The exoprotease LepA cleaves and activates PAR1, PAR2, and PAR4, and subsequently induces nuclear factor kappa B (NFκB) promoter activity \[[@CR100]\], whereas cleavage by elastase EPa inactivates PAR2 to prevent inflammation in lungs \[[@CR101]\].

The streptococcal pyrogenic exotoxin B (SpeB) of Group A *Streptococcus* also inactivates PAR1 by cleaving it, and thereby renders human platelets unresponsive to thrombin \[[@CR102]\]. In mice, proteases of *Streptococcus pneumoniae* cleaved PAR2 and facilitated the spread of the pathogen from the airways into the blood stream \[[@CR103]\]. PAR1 has also been associated with *S. pneumonia-*mediated sepsis in mice, although direct cleavage of PAR1 was not shown \[[@CR104], [@CR105]\]. Pulmonary inflammation from *S. pneumoniae* infections is reduced in PAR4 knockout mice \[[@CR106]\], further supporting this causal link.

Inflammation-associated periodontal diseases are predominantly induced by the *Porphyromonas gingivalis* cysteine protease gingipain R, which activates PAR2 \[[@CR107], [@CR108]\]. Subsequently, gingipain R activates PAR1 and PAR4, and thereby, human platelets \[[@CR109]--[@CR111]\]. This mechanism may also explain associations between periodontitis and cardiovascular events \[[@CR112]\].

In addition, supernatants from *Propionibacterium acnes* cultures initiated inflammatory signaling in human keratinocytes via PAR2 \[[@CR92]\]. The virulence of *P. acnes* was also reduced in PAR2 knockout mice \[[@CR113]\], further suggesting that PAR2 is involved in bacterial infections.

Serralysin is a matrix metalloprotease expressed by *Serratia marcescens*, and induced inflammation in human airway cells via PAR2 in vitro \[[@CR114]\].

Finally, *Bacillus thermoproteolyticus rokko* secretes the metalloprotease thermolysin, which cleaves and inactivates PAR1 to prevent thrombin-induced signaling in rat astrocytes \[[@CR115], [@CR116]\]. The in vitro effects of PAR2-cleavage by thermolysin, however, vary between cell lines \[[@CR116]\].

#### Amoeba proteases {#FPar5}

In acanthamoebic keratitis, PAR2 triggers inflammation following secretion of the plasminogen activator (aPA) by *Acanthamoeba* strains, leading to induction of IL-8 in human corneal epithelial cells \[[@CR117]\].

#### Reptile proteases {#FPar6}

Following snakebites, coagulation disorders in humans and mice occur due to the presence of venom proteases. In *Proatheris superciliaris* bites, venom proteases activate platelets by activating PAR1 and PAR4 \[[@CR118]\]. *Bothrops atrox* and *B. jararaca* are snake species of the family viperidae. These snakes secrete the serine proteases PA-BJ and thrombocytin, which activate human platelets via PAR1 and PAR4 \[[@CR119]\].

#### Insect proteases {#FPar7}

Several cysteine and serine proteases from insects induce inflammation-associated diseases such as asthma. For example, dust mite allergens contain the serine proteases DerP2, DerP3, and DerP9 \[[@CR120]\] and the cysteine protease DerP1. DerP1 induces PAR2-dependent signaling, whereas thrombin-induced PAR1-signaling is prevented by these proteases in human epithelial cells \[[@CR121]\]. DerP3 was also recently shown to activate PAR4, and this process was associated with allergies to dust mites \[[@CR122]\].

Similar to proteases from house dust mites, three serine proteases (E1--E3) from cockroach extracts activate PAR2 and induce inflammatory signaling in mice and humans \[[@CR123]--[@CR125]\].

#### Fungal proteases {#FPar8}

Pen C is a serine protease from *Penicillium citrinum* that induces IL-8 in human airway cells by activating PAR1 and PAR2 \[[@CR126]\]. Proteases from *Aspergillus fumigatus* have also been shown to prevent PAR2-dependent inflammation \[[@CR127]\]. Moreover, serine proteases from *Alternaria alternate* induced calcium signaling in human bronchial cells and induced inflammation in mice by secreting IL-33 following PAR2 activation \[[@CR128]--[@CR130]\].

#### Plant proteases {#FPar9}

Bromelain is a mixture of cysteine proteases that is extracted from pineapple which is used as a PAR-independent anti-inflammatory agent \[[@CR131]\]. Bromelain cleaves PAR2 and thereby prevents the associated inflammatory signaling \[[@CR132]\]. In another study, however, bromelain, ficin, and papain activated PAR2 and PAR4 by proteolytic cleavage, leading to increased intracellular calcium levels \[[@CR133]\]. Thus, further studies are required to further clarify the modes of action of pineapple proteases.

Cleavage-independent PAR activation by agonist peptides {#Sec6}
-------------------------------------------------------

Independent of proteolytic cleavage, PARs can be activated by synthetic soluble ligands corresponding with cleaved N-terminal sequences, or can be transactivated by cleavage-generated N-terminal regions of homo- or heterodimer partners.

Synthetic peptides that mimic the first six amino acids of tethered N-terminal ligands can act as agonist peptides that activate PARs in the absence of cleavage events \[[@CR11], [@CR18], [@CR134]\]. Specific activation of PARs by a soluble agonist peptide was first shown for human PAR1 with the peptide SFLLRN \[[@CR6], [@CR18]\]. However, this peptide also activated PAR2 \[[@CR135]--[@CR137]\] and therefore various peptides were tested for specific PAR1 activation. Yet, PAR1 was the most specifically and efficiently activated by TFLLRN \[[@CR138]\]. In addition to thrombin agonist peptides, other PAR1 agonist peptides have been identified. In particular, the peptide NPNDKYEPF reproduced the effects of aPC \[[@CR28]\], and PRSFFLRN corresponds with the N-terminal peptide generated by MMP-1 \[[@CR86]\]. SLIGKV corresponds with the trypsin cleaved N-terminal region of human PAR2. However, the corresponding rat N-terminus SLIGRL is a more specific and efficient PAR2 agonist in rodents and humans \[[@CR136], [@CR139]\], and only the synthetic peptide LIGRLO achieved this effect more efficiently than SLIGRL in humans \[[@CR140]\]. The roles of ECL-2 in specific PAR activation have been shown using labeled PAR2 agonist peptides \[[@CR141], [@CR142]\]. Because the thrombin generated PAR3 peptide does not activate the G protein autonomously, no such agonist peptides have been identified to date \[[@CR9], [@CR143]\]. GYPGKF corresponds with the thrombin-cleaved human PAR4 and has weak activity as an agonist \[[@CR144]\]. But replacement of the first amino acid glycine (G) with alanine (A) induced PAR4 by 10-fold. This peptide may be suitable as a platelet activator in humans and mice \[[@CR145]\].

Several models of PAR--PAR interactions have been proposed and extensively studied based on PAR transactivation by agonist peptides \[[@CR146]\]. When PAR1 is blocked on endothelial cells, however, thrombin, and not the PAR1-specific agonist peptide TFLLRN, induces signaling, reportedly by facilitating the heterodimerization of PAR1 and PAR2 \[[@CR147]\]. Thrombin activation of the PAR1--PAR2 heterodimer leads to constitutive internalization and activation of β-arrestin by the PAR1 C-tail \[[@CR146]\]. Accordingly, the required co-localization of PAR1 and PAR2 was shown in a human overexpression system, in mice studies of sepsis, and in PAR1--PAR2-driven cancer growth in a xenograft mouse model \[[@CR148], [@CR149]\]. In other studies, stable heterodimerization of human PAR1 and PAR4 was shown in platelet cells, and thrombin accelerated platelet activation under these conditions \[[@CR150], [@CR151]\]. Similar studies of mouse platelets showed efficient activation of platelets by thrombin in the presence of PAR3--PAR4 heterodimers \[[@CR143]\]. Consistent with the thrombin-cleaved PAR3 peptide, which is not self-activating, PAR3 signaling was observed in the presence of PAR1 or PAR2 \[[@CR22], [@CR23], [@CR34], [@CR152]\]. Yet, heterodimerization influenced signal transduction and PAR membrane delivery due to enhanced glycosylation \[[@CR153]\].

In addition to activation by heterodimerization, PARs interact with other receptors, such as ion channels, other G protein-coupled receptors (GPCRs), receptor tyrosine kinases (RTKs), receptor serine/threonine kinases (RSTKs), NOD-like receptors, and TLRs \[[@CR154]\]. In particular, PAR2 initiated inflammatory signaling pathways, resulting in pain due to transactivation of the ion channels TRPV1 and TRPV4 in humans and mice \[[@CR155]--[@CR159]\]. Similar inflammatory effects follow transactivation of the RTKs EGFR and VEGFR by PAR2 and PAR4 \[[@CR160]--[@CR163]\]. Bacterial interactions with PARs suggest important roles of PARs in infectious disease. In agreement, TLRs recognize bacteria-derived molecules and contribute to innate immunity \[[@CR164], [@CR165]\]. Moreover, direct interactions of PAR2 with TLR3 and TLR4 were necessary for inflammatory responses to LPS in human cell lines and knockout mice and rats \[[@CR166]--[@CR171]\].

PAR signaling {#Sec7}
-------------

### Activation pathways {#Sec8}

PARs belong to a large family of GPCRs and induce multiple signaling pathways after coupling with heterodimeric G proteins. Activation of the Gα-subunit due to the exchange of a guanine from GDP to GTP results in dissociation of the Gβγ-dimer and activation of downstream pathways \[[@CR172], [@CR173]\].

Following proteolytic cleavage or induction of agonist peptides, the engaged signaling pathways vary between tissues, cell lines, and the availability of co-receptors for transactivation. Depending on the ligand, specific α-subunits are activated, and these regulate subsequent cellular functions as summarized in Fig. [4](#Fig4){ref-type="fig"}. For example, thrombin-stimulated PAR1 activates the small GTPase protein RhoA via ERK1/2 kinases, but not via Rac1, whereas aPC-stimulated PAR1 induces Rac1 via Akt kinase, but not via RhoA \[[@CR13], [@CR174]--[@CR176]\]. Moreover, in accordance with PAR1 cleavage sites, aPC prevents thrombin-induced RhoA signaling \[[@CR16]\]. However, in contrast with thrombin-induced RhoA activation on platelets and endothelial cells, PAR1-agonist peptides and thrombin activated the inhibitory G protein G~i~ which leads to the inhibition of adenylyl cyclase in human fibroblasts \[[@CR177], [@CR178]\]. Other studies indicate that PAR2 activation is less tissue specific than PAR1 activation, and trypsin and VIIa cleaved PAR2 and activated G~αq~ and G~i~, resulting in calcium influx, MAPK activation, and inflammatory signaling \[[@CR8], [@CR179]\].Fig. 4G protein-coupled signaling induced by PAR activation. Depending on the tethered ligand, activated PAR couples with G protein α-subtypes. Gαq activates phospholipase Cβ (PLCβ), which mobilizes calcium. This further activates MAPKs (ERK1/2) and induces Ras signaling. Primarily, Gα12/12 and Gaq activate the Rho pathway. Gαi inhibits the activation of adenylyl cyclase, which leads to reduced production of cAMP. In contrast, the βγ-subunit functions as a negative regulator when bound to the α-subunit. After receptor activation, subunits separate, and the βγ-subunit interacts with other proteins, thereby activating or inhibiting signaling

Signaling by tethered ligands can differ from that generated by corresponding soluble agonist peptides. For example, thrombin-cleaved PAR1 activated G~α12/13~ and G~αq~ and induced Rho and Ca^2+^ signaling, whereas the PAR1-agonist peptide activated only G~a12/13~ and downstream RhoA-dependent pathways that affected endothelial barrier permeability \[[@CR180]\]. Similar observations of human platelets suggested that platelet activation followed coupling of thrombin-activated PAR1 with multiple heterotrimeric G protein subtypes, including G~α12/13~ and G~αq~ \[[@CR181]--[@CR183]\]. Moreover, trypsin and the PAR2-agonist peptide induced ERK1/2 signaling and inflammation by activating PAR2 \[[@CR29], [@CR180], [@CR184]--[@CR186]\]. β-arrestins also play major roles in PAR-induced signaling independently of G protein activation. For instance, aPC-activated PAR1 induces cytoprotective effects by recruiting β-arrestin in endothelial cells. Thus, aPC cleavage fails to protect β-arrestin deficient cells from the effects of thrombin \[[@CR187], [@CR188]\]. In addition, multiple studies show that activated PAR2 co-localizes with β-arrestin-1 and arrestin-2 and induces ERK1/2 signaling \[[@CR77], [@CR189]--[@CR191]\].

### Desensitization and termination {#Sec9}

PAR activation is regulated by internalization and proteolytic desensitization, which limits the duration of signaling. For instance, PAR1 is constitutively internalized and recycled or agonist-induced internalized and degraded as described in \[[@CR192], [@CR193]\] and shown in the scheme of Fig. [5](#Fig5){ref-type="fig"}. As discussed above, some PAR-cleaving proteases abolish receptor responses by removing (shedding) or destroying the tethered ligands. For example, PAR1 is inactivated following cleavage by cathepsin G, and thrombin activation is hence prevented, allowing the formation of clotting under inflammatory conditions.Fig. 5PAR trafficking. Activation-independent constitutive or agonist-induced internalization regulates PAR1 signaling

Depending upon proteolytic cleavage, PAR1 rapidly internalizes or accumulates on the cell surface \[[@CR194], [@CR195]\]. Activated PAR1 is internalized via clathrin- and dynamin-dependent mechanisms, and is sorted from early endosomes to lysosomes for degradation \[[@CR196]--[@CR199]\]. Although the mechanisms that terminate PAR1 signaling are not clearly understood, this process is known to involve phosphorylation, ubiquitination, and recruitment of β-arrestin \[[@CR200]--[@CR204]\]. In contrast with PAR1, activated PAR2 is not constitutively internalized \[[@CR205]\]. Thus, to prevent persistent signaling upon activation, PAR2 is phosphorylated and ubiquitinated and then binds β-arrestin before being internalized and degraded \[[@CR206]--[@CR208]\]. Under these conditions, the activated and internalized PAR2 is not recycled and instead induces β-arrestin-dependent endosomal ERK1/2 signaling in the cytoplasm \[[@CR189], [@CR191], [@CR209]\]. Thus, large cytoplasmic stores of newly generated PAR2 are required for rapid externalization and activation on cell membranes \[[@CR210]\]. Although less is known about how PAR4 signaling is terminated, recent observations suggest that PAR4 internalization is independent of β-arrestin and slowly occurs via clathrin- and dynamin-dependent pathways \[[@CR211]\]. In agreement, human platelets internalized PAR4 much slower than PAR1, and exhibited prolonged PAR4 signaling activity \[[@CR212]\]. Moreover, growing evidence indicates that PAR--PAR heterodimerization is important for internalization, and that the underlying mechanisms include PAR2-dependent glycosylation of PAR4, thus affecting membrane transport \[[@CR153]\]. Upon internalization, endosomal PAR4 dimerizes with the purinergic receptor P2Y12 and induces Akt signaling by recruiting β-arrestin within endosomes \[[@CR213]\].

Depending on stimuli, PAR expression patterns are regulated by complex combinations of cell surface presentation, endocytosis, vesicle born or recycled (i.e., re-exocytosed) receptors, and trafficking modes that are linked to posttranslational modifications of PAR.

Role of PARs in inflammation {#Sec10}
============================

With the current increases in the prevalence of inflammatory diseases, published in in vitro and in vivo studies of the roles of PARs in inflammation have become more numerous. These are reviewed below.

Systemic inflammation and inflammatory cells in the cardiovascular system {#Sec11}
-------------------------------------------------------------------------

PARs are critical for the interplay between clotting proteases of platelets, endothelial cells, and vascular smooth muscle cells that regulate hemostasis, vascular barrier function, vascular tone, vascular homeostasis, cell adhesion, and inflammatory responses \[[@CR150]\]. The roles of PARs in these processes vary significantly between species. Specifically, whereas functional PAR1 and PAR4 are expressed in human platelets \[[@CR214]\], PAR1, PAR3, and PAR4 have been found in guinea pig platelets \[[@CR215]\]. Whereas mouse and rat platelets lack PAR1, they are activated at low concentrations of thrombin, which is recruited by PAR3 onto the surface of platelets and then efficiently activates PAR4 \[[@CR4]\]. Due to interspecies differences in PAR expression, mouse and rat studies of PARs are difficult to translate to humans. PARs in endothelial cells contribute positive regulatory signals for endothelial adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and E-selectin \[[@CR216], [@CR217]\], all of which promote vascular barrier function. As a counterpart of intravascular cells, PAR4 induces leukocyte migration \[[@CR75]\], and PAR2 expressed on macrophages promotes inflammatory modulators such as interleukin-8 (IL-8) \[[@CR218]\]. These modes of signaling all contribute to a complex PAR-mediated interplay of endothelial cells that is orchestrated by intravascular cells and cytokine secretion. In addition, PARs, particularly PAR1, regulate vascular barrier function, and hence, extravasation of macromolecules such as complement proteins and antibodies. In addition, thrombin-mediated activation of PAR1 increases endothelial barrier permeability by activating mitogen-activated protein kinases (MAPKs) \[[@CR219]\]. Although this effect is reversed by activated protein C (aPC)-mediated activation of PAR1 \[[@CR28], [@CR174], [@CR175], [@CR220]\]. Thrombin further promotes prostaglandin 2 (PGE2) secretion, and consequent endothelial barrier permeability \[[@CR221]\]. Similarly, PAR1 activation increased vascular leakage in a murine model \[[@CR222]\]. Inflammatory mediators, such as tumor necrosis factor alpha (TNFα), were shown to regulate the expression of endothelial PAR2, and the authors suggested that these data were indicative of barrier protective effects of PAR2 \[[@CR223]\]. Several other studies show that PAR2 activation induces endothelium-dependent relaxation in blood vessels of mice and in arteries of rats \[[@CR224]--[@CR228]\]. In contrast, dual activities of PAR2 on blood vessels were reported in a study of rats \[[@CR229]\]. In this line, thrombin-activated PAR1 induced the expression of vascular endothelial growth factor in smooth muscle cells \[[@CR230]\], thus revealing the relationship between coagulation and vascular growth. Although the roles of PARs in the development of arteriosclerosis are yet to be elucidated, PAR2 and PAR4 were induced in human arteries under inflammatory conditions \[[@CR223]\], suggesting important roles of PARs in vascular inflammation.

Chronic inflammation of the gastrointestinal tract {#Sec12}
--------------------------------------------------

In the gut lumen, human and bacterial proteases are both present at high concentrations. Similar to endothelial barriers, proteases regulate intestinal barrier permeability via PARs, all four of which are expressed by cells of the gastrointestinal tract \[[@CR9], [@CR224], [@CR231], [@CR232]\]. Trypsins and tryptases are prominent intestinal proteases, suggesting likely involvement of PAR2 as a major receptor of intestinal inflammation. In accordance, intestinal tight junctions are disrupted by PAR2-activating proteases, leading to inflammatory signaling in humans and rats \[[@CR139], [@CR206], [@CR233], [@CR234]\]. Although the roles of PARs in irritable bowel syndrome (IBS) and inflammatory bowel diseases remain unclear, roles of PARs in intestinal barrier function have been described. Specifically, PAR1 and PAR2 regulated permeability and chloride secretion, which are involved in diarrhea and constipation in IBS patients \[[@CR234]--[@CR236]\]. In addition, activated endosomal PAR2 caused persistent pain in a mouse model of IBS \[[@CR209]\].

Inflammatory diseases of the respiratory system {#Sec13}
-----------------------------------------------

It has long been suggested that PARs are involved in the pathophysiology of respiratory disorders, reflecting observations of elevated levels of PAR-activating proteases, such as thrombin and tryptase, in bronchoalveolar lavage fluid from patients with pulmonary inflammation \[[@CR237], [@CR238]\]. In a sheep asthma model and in asthmatic patients, tryptase inhibitors reduced inflammation \[[@CR239], [@CR240]\], further indicating important roles of PAR2 in respiratory disease. These roles of PARs are also suggested by the prominence of a variety of non-mammalian PAR-activating proteases, such as those of house dust mites and cockroaches \[[@CR120], [@CR123], [@CR124]\]. Expression of PAR1, PAR2, and PAR4 on bronchial epithelial and smooth muscle cells induced inflammatory signaling in multiple studies \[[@CR55], [@CR121], [@CR241]--[@CR245]\]. PAR2 is also upregulated in epithelial cells of patients with asthma and chronic obstructive pulmonary syndrome (COPD) \[[@CR246], [@CR247]\]. Whether PAR2 activation results in bronchoconstriction or dilatation remains controversial, in part owing to interspecies differences and tissue dependencies \[[@CR242], [@CR248], [@CR249]\]. In humans, however, PAR1-agonist peptides with thrombin, and a PAR2-agonist peptide with trypsin and tryptase, induced bronchoconstriction by inducing Ca^2+^ signaling in airway smooth muscle cells \[[@CR241], [@CR244]\]. Moreover, the long-term activation of PAR1 and PAR2 led to pulmonary fibrosis in mice models \[[@CR250]\].

Inflammatory skin diseases {#Sec14}
--------------------------

High concentrations of exogenous proteases are present on the skin of various species, and these may activate PARs to regulate epidermal permeability and barrier function \[[@CR251]\]. Indeed, epidermal inflammation has been linked to PAR1 and PAR2 activation in keratinocytes, which comprise the epidermal barrier with sub-epidermal skin fibroblasts \[[@CR179], [@CR252], [@CR253]\]. Subsequent release of IL-8, IL-6, and granulocyte macrophage colony-stimulating factor (GM-CSF) was also observed previously \[[@CR254]\], potentially involving NFκB activation \[[@CR255]\]. In addition, the inflammatory roles of PAR2 have been demonstrated in mice models of atopic dermatitis due to elevated tryptase and PAR2 expression levels \[[@CR256], [@CR257]\]. Similar to studies in mouse models, PAR2 was upregulated in patients with atopic dermatitis, and PAR2 agonists increased itch, causing irresponsiveness of sensory nerves to therapy with antihistamines \[[@CR258]\].

Rheumatic disease {#Sec15}
-----------------

"Rheumatic disease" is a common term for autoimmune diseases that affect joints, bones, and muscles. Although rheumatic disorders are numerous, some of the common underlying symptoms include chronic joint inflammation, stiffness, and pain \[[@CR259]\]. Currently, PAR2 is the only PAR that has been associated with the development of rheumatic diseases \[[@CR260]\]. Direct roles of PAR2 in rheumatic diseases were first indicated in 2003 in a mouse study by Ferrell et al. \[[@CR261]\]. In their study, a PAR2-agonist peptide induced strong inflammatory effects in wt mice, causing joint swelling and synovial hyperemia, whereas joint swelling was absent in PAR2 deficient mice \[[@CR261]\]. Similarly, in patients with rheumatoid arthritis, PAR2 is upregulated in inflamed tissues \[[@CR262]\]. Further increases in PAR2 expression were noted in monocytes, and the PAR2-agonist peptide upregulated IL-6. In contrast, PAR2 expression was decreased after treatments with antirheumatic drugs \[[@CR263]\], further supporting the role of PAR2 in rheumatic disease.

PAR modulators as targets for therapy {#Sec16}
=====================================

The complexity of PAR regulation is indicated by the culmination of specific proteolytic cleavage modes (inactivating or activating), protease inhibitors, and cofactors, and with the effects of PAR glycosylation and dimerization (Fig. [1](#Fig1){ref-type="fig"}). In this section we discuss classes of agonists and antagonists that have been tested as PAR modulators for use as therapeutic agents as summarized in Fig. [6](#Fig6){ref-type="fig"} and Tables [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}.Fig. 6PAR modulators. Pharmacological substances, such as 1) peptides and peptidomimetics, 2) blocking antibodies, 3) small molecules, 4) pepducins, and 5) parmodulins are used as therapeutic agents that affect PAR activitiesTable 5PAR1 signaling modulatorsClassAgonist/ AntagonistNameReceptor/Cell/Tissue typeCellular responsePeptideAgonistSFLLRN/−NH2HumanInduces platelet activation \[[@CR6], [@CR138], [@CR265], [@CR278], [@CR279]\]TFLLRN/−NH2HumanInduces platelet activation, enhances endothelial barrier permeability \[[@CR137], [@CR138], [@CR265]\]NPNDKYEPF/−NH2HumanInduces cytoprotective signaling \[[@CR28], [@CR187]\]PRSFLLRN/−NH2HumanInduces platelet activation \[[@CR86]\]HumanInduces ERK1/2 activation \[[@CR280]\]AntagonistYFLLRNHumanCompets with thrombin and PAR1-AP and prevents platelet activation \[[@CR278], [@CR279]\]PeptidomimeticAntagonistRWJ-56110HumanBlunts thrombin and PAR1-AP effects on platelets and vascular endothelial cells \[[@CR264], [@CR281], [@CR282]\]HumanBlocks MMP-1 activaiton in SMCs \[[@CR87]\]RWJ-58259Guinea pigBlocks thrombin and PAR1-AP platelet activation \[[@CR215], [@CR283]\]RatBlocks thrombin induced calcium release in AoSMC Inhibits intimal thickening \[111, 215, 264, 273\]MousePrevents destruction of intestinal barrier \[[@CR62], [@CR284]\]Non-peptide small moleculeAntagonistFR17113HumanBlocks PAR1-AP induced platelet activation \[[@CR285], [@CR286]\]HumanInhibits thrombin and PAR1-AP induced ERK1/2 activation \[[@CR287]\]ER129614--06HumanBlocks thrombin and PAR1-AP induced platelet activation \[[@CR288]\]Guinea pigShows antithrombotic effects \[[@CR289]\]F16357, F16618HumanBlocks PAR1-AP induced platelet activation \[[@CR290]\]RatShows antithrombotic effects \[[@CR291]\]SCH79797HumanBlocks thrombin and PAR1-AP induced calcium release and platelet activation \[[@CR292]\]Human, MouseInduces NETs formation and increases bacterial killing capacity \[[@CR293]\]SCH203009HumanBlocks thrombin and PAR1-AP induced platelet activation \[[@CR292]\]SCH530348 (vorapaxar)Human, MonkeyBlocks thrombin and PAR1-AP induced platelet activation \[[@CR266]\]E5555 (atopaxar)HumanBlocks thrombin and PAR1-AP induced platelet activation and inhibits thrombus formation \[[@CR267]\]Guinea pigBleeding time not affected \[[@CR267], [@CR294]\]Q94HumanBlocks thrombin induced calcium release \[[@CR295]\]MouseBlocks thrombin induced ERK1/2 activation \[[@CR296]\]PepducinAntagonistP1pal-12HumanBlocks thrombin induced platelet activation \[[@CR268]\]HumanBlocks platelet activation \[[@CR86]\]HumanBlocks MMP-1 induced endothelial damage \[[@CR297]\]MouseReduces lung vascular damage and sepsis lethality \[[@CR297], [@CR298]\]P1-pal7\
(PZ-128)HumanBlocks MMP-1 induced Akt signaling in cancer cells \[[@CR150]\]HumanBlocks platelet activation \[[@CR86]\]MouseInhibits tumor growth \[[@CR280]\]Guinea pigPrevents from systemic platelet activation \[[@CR86]\]ParmodulinAntagonistML161 (Parmodulin-2)HumanBlocks thrombin and PAR1-AP induced platelet activation \[[@CR299]\]HumanBlocks thrombin induced inflammatory signaling on endothelial cells \[[@CR269]\]MouseBlocks thrombus formation \[[@CR300]\]AntibioticAntagonistDoxycyclineHumanInhibits thrombin induced cancer cell migration \[[@CR301], [@CR302]\]HumanBlocks MMP-1 cleavage \[[@CR303]\]AntibodyAntagonistATAP-2\
WEDEHumanBlocks thrombin cleavage of PAR1 and thrombin induced calcium release \[[@CR147]\]Table 6PAR2 signaling modulatorsClassAgonist/ AntagonistNameReceptor/Cell/Tissue typeCellular responsePeptideAgonistSLIGRL/−NH2Human, RatInduces calcium release \[[@CR2], [@CR8], [@CR136], [@CR139]\]SLIGKV/−NH2HumanInduces calcium release \[[@CR136]\]2f-LIGRLO/−NH2Human, RatInduces calcium release \[[@CR140]\]AntagonistFSLLRY-NH2HumanBlocks trypsin, not SLIGRL activation, reduces proinflammatory IL-8 and TNFα \[[@CR82]\]RatInhibits neuropathic pain \[[@CR304]\]LSIGRL-NH2HumanBlocks trypsin, not SLIGRL induced calcium release \[[@CR305]\]PeptidomimeticAntagonistK14585,\
K12940HumanReduces SLIGKV induced calcium release \[[@CR306]\]HumanInhibits SLIGRL induced NFkB activation \[[@CR307]\]C391aHuman, MouseBlocks calcium release and MAPK activation \[[@CR308]\]Non-peptide small moleculeAgonistGB110HumanInduces calcium release \[[@CR309]\]AC-5541,\
AC-264613HumanInduces calcium release \[[@CR310]\]RatInduces edema and hyperalgesia \[[@CR310]\]AntagonistENMD-1068HumanBlocks p.acnes induced calcium release and induction of IL-1a, IL-8 and TNFα \[[@CR92]\]HumanInhibited FVIIa induced cancer cell migration \[[@CR311]\]MouseReduces joint inflammation \[[@CR260]\]MouseBlocks calcium release and reduces liver fibrosis \[[@CR312]\]GB83HumanInhibits trypsin and PAR2-AP calcium release \[[@CR313]\]GB88HumanBlocks PAR2 induced calcium release \[[@CR309]\]RatReduces acute paw edema, inhibits PAR2-AP induced inflammation \[[@CR309], [@CR314]\]AZ8838\
AZ3451HumanBlocks PAR2-AP induced calcium release and β-arrestin recruitment \[[@CR315]\]PepducinAntagonistP2pal-18SHumanBlocks PAR2 induced calcium release \[[@CR316]\]MouseDecreases risk for developing severe biliary pancreatitis \[[@CR317]\]P2pal-14GQHumanBlocks PAR2 induced calcium release \[[@CR316]\]AntibioticAntagonistTetracyclines\
(Tetracycline,\
Doxycycline,\
Minocycline)HumanInhibits SLIGRL induced IL-8 release \[[@CR318]\]MouseTopical application of tetracycline decreases PAR2 induced skin inflammation \[[@CR319]\]RatSubantimicrobial doses of doxycycline inhibit PAR2 induced inflammation \[[@CR320]\]AntibodySAM-11MouseReduces joint inflammation \[[@CR260]\]MousePrevents allergic inflammation \[[@CR124]\]B5MouseReduces joint inflammation \[[@CR260]\]MouseInhibits allergic airway inflammation \[[@CR124]\]MAB3949HumanBlocks trypsin induced PAR2 activation \[[@CR315]\]Table 7PAR4 signaling modulatorsClassAgonist/ AntagonistNameReceptor/Cell/Tissue typeCellular responsePeptideAgonistGYPGQV/−NH2Human, RatInduces platelet activation \[[@CR144]\]GYPGKF/−NH2Human, RatInduces platelet activation \[[@CR144]\]AYPGKF/−NH2Human, MouseInduces platelet activation \[[@CR145]\]PeptidomimeticAntagonisttc-YGPKFRatBlocks thrombin and PAR4-AP induced platelets aggregation \[[@CR321]\]Non-peptide small moleculeAntagonistYD-3HumanBlocks thrombin induced platelet activation \[[@CR282], [@CR322]--[@CR325]\]Mouse, Rat, RabbitBlocks thrombin and PAR4-AP induced platelets activation \[[@CR323]--[@CR325]\]ML-354HumanBlocks PAR4-AP induced platelet activation \[[@CR326]--[@CR328]\]BMS-986120HumanBlocks PAR4-AP induced calcium release and platelet activation \[[@CR329]\]HumanBlocks thrombus formation at high shear stress \[[@CR277]\]MonkeyBlocks platelet activation \[[@CR329]\]PepducinAntagonistP4pal-10Human, MouseBlocks thrombin and PAR4-AP induced platelet activation \[[@CR268]\]RatBlocks thrombin and PAR4-AP induced platelets activation \[[@CR330]\]P4pal-i1HumanBlocks PAR4 induced platelets activation \[[@CR150]\]

Peptide agonists and antagonists are short synthetic peptides that mimick the PAR-tethered ligand that is liberated by proteolytic cleavage, as described above. These peptides either induce signal transduction or prevent cleavage-dependent signaling following PAR rapid internalization, and some C- or N-terminal modifications of soluble ligand sequences have resulted in increased activation efficiency \[[@CR18]\]. Peptidomimetic antagonists are small protein-like chains that mimick the tethered ligands of PARs, and were recently used as PAR modulators for the first time \[[@CR264]\].Soon after PARs were discovered, PAR1 blocking antibodies were reported \[[@CR265]\], and these blocked protease binding and or the cleavage site of the receptor. Non-peptide small molecules, such as the PAR1 antagonists vorapaxar \[[@CR266]\] and atopaxar \[[@CR267]\], also interact with PARs, mainly via ECL2.Only two classes of intracellular PAR antagonists have been developed to date. Pepducins are cell penetrating palmitoylated peptides that were derived from the intracellular loop of PAR, and these interfere with G protein binding \[[@CR268]\]. Parmodulins, in contrast, are small molecules that bind PARs at the G protein binding pocket of the C-tail to compete with G~αq~ subunits, but not with other G~α~ subunits \[[@CR269]\].

Examination of agonists and antagonists in vitro and in preclinical studies (Tables [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}) {#Sec17}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Clinical studies {#Sec18}
----------------

Despite the importance of PARs in various pathophysiological conditions, few PAR modulating tools have been tested in clinical studies, and even fewer have been established for treatment. Since the identification of PAR1 as a platelet thrombin receptor, an abundance of research has been conducted to identify PAR1 antagonists that can block platelet activation and prevent thrombotic cardiovascular events. The first clinically approved PAR1 antagonist was the small-molecule antagonist vorapaxar \[[@CR266]\]. Phase II clinical trials of this agent showed reduced risks for myocardial infarction in patients treated with vorapaxar in combination with standard antiplatelet therapy. Moreover, the risks of bleeding complications were not significantly increased \[[@CR270]\]. Subsequently, two large-scale phase III multicenter, randomized, double-blind, placebo-controlled studies of vorapaxar (ZONTIVITY, SCH530348) were performed. In the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events--Thrombolysis in Myocardial Infarction 50 (TRA 2°P-TIMI 50; details at [www.ClinicalTrials.gov](http://www.clinicaltrials.gov); [NCT00526474](https://www.clinicaltrials.gov/ct2/show/NCT00526474)) study, the rate of cardiovascular events at the second efficacy endpoint were significantly reduced by vorapaxar in combination with standard antiplatelet therapy \[[@CR271]\]. Furthermore, in the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER; details at [www.ClinicalTrials.gov](http://www.clinicaltrials.gov); [NCT00527943](https://www.clinicaltrials.gov/ct2/show/NCT00527943)) study, vorapaxar reduced the hazard of first myocardial infarction of any type in patients who were treated within 24 h of having symptoms of a cardiovascular event. However, in the TRACER study, vorapaxar failed to prevent secondary ischemic events \[[@CR272]\]. Because vorapaxar increased bleeding complications in the clinical setting, the alternative PAR1 antagonist atopaxar (E5555) \[[@CR267]\] was tested in a phase II clinical trial called (Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes (LANCELOT-ACS; details at [www.ClinicalTrials.gov](http://www.clinicaltrials.gov); [NCT00548587](https://www.clinicaltrials.gov/ct2/show/NCT00548587)) study \[[@CR273]\]. Atopaxar inhibited platelet aggregation in ACS patients in a dose-dependent manner, and caused no side effects of abnormal platelet activation, such as bleeding \[[@CR274], [@CR275]\]. Yet, patients receiving atopaxar had dose-dependent increases in liver abnormalities \[[@CR273]\].

To prevent the bleeding problems that arise from treatments with PAR1 antagonists, a new class of PAR1 antagonist was designed, and the member pepducin PZ-128 (P1-pal7) was tested in a phase I trial \[[@CR276]\]. This study showed no reduction in platelet aggregation, but the platelet blocking effect of PZ-128 was reversible ex vivo in the presence of saturating concentrations of the PAR1 agonist peptide SFLLRN. Based on these promising findings, the new PAR1 blocking agent PZ-128 was considered in the coronary artery disease study Thrombin Receptor Inhibitory Pepducin-Percutaneous Coronary Intervention (TRIP-PCI). Data from this phase II trial are not yet available (details at [www.ClinicalTrials.gov](http://www.clinicaltrials.gov); [NCT02561000](https://www.clinicaltrials.gov/ct2/show/NCT02561000)).

As an alternative to PAR1 targeted antithrombotic drugs, the PAR4 small-peptide antagonist BMS-986120 reduced reversible thrombus formation ex vivo in a phase I trial \[[@CR277]\]. Consequently, this promising anticoagulant PAR4 antagonist is currently being compared with a standard anticoagulant drug in a phase II study of stroke recurrence (details at [www.ClinicalTrials.gov](http://www.clinicaltrials.gov); [NCT02671461](https://www.clinicaltrials.gov/ct2/show/NCT02671461)).

Conclusion {#Sec19}
==========

Since the identification of PARs in the 1990s, studies of the complex mechanisms of PAR activation have been abundant, and these have clarified the roles of PARs in inflammatory disease. Various mammalian and non-mammalian proteases have also been recognized as PAR-mediated regulators of physiological and pathophysiological processes. Despite the development of various PAR modulators, few have been approved for therapeutic use. Obstacles to this therapeutic strategy include species differences in PAR expression and limited bioavailability of modulators in vivo and in clinical studies. Further research is needed to identify specific and efficient anti-inflammatory PAR modulators.

AC

:   Adenylyl Cyclase

AKT

:   Protein kinase B

aPC

:   Activated Protein C

COPD

:   Chronic Obstructive Pulmonary Syndrome

COX

:   Cyclooxygenase

ECL

:   Extracellular Loop

EGFR

:   Epidermal Growth Factor Receptor

EPCR

:   Endothelial Protein C Receptor

ERK

:   Extracellular Signal-regulated Kinase

F2R

:   Coagulation Factor 2 Receptor

F2RL1

:   Coagulation Factor 2 Receptor-Like 1

F2RL2

:   Coagulation Factor 2 Receptor-Like 2

F2RL3

:   Coagulation Factor 2 Receptor-Like 3

FVIIa

:   Activated Coagulation Factor VII

FXa

:   Activated Coagulation Factor X

GM-CSF

:   Granulocyte Macrophage Colony-stimulating Factor

GPCR

:   G Protein-Coupled Receptor

IBD

:   Inflammatory Bowel Disease

IBS

:   Irritable Bowel Syndrome

ICAM

:   Intercellular Adhesion Molecule

IL

:   Interleukin

LepA

:   *Pseudomonas aeruginosa*-Derived Large Extracellular Protease

LPS

:   Lipopolysaccharides

MAPK

:   Mitogen-Activated Protein Kinase

MMP

:   Matrix Metalloprotease

NFκB

:   Nuclear Factor kappa B

PAR

:   Protease-Activated Receptor

penC

:   Penicillium citrinum-Derived Alkaline Serine Protease C

PGE2

:   Prostaglandin E2

PI3K

:   Phosphatidylinositol-3-Kinase

PLCβ

:   Phospholipase C beta

Rac1

:   Ras-Related C3 Botulinum Toxin Substrate 1

RhoA

:   Ras homolog gene family, member A

RSTK

:   Receptor Serine/Threonine Kinase

RTK

:   Receptor Tyrosine Kinase

SpeB

:   Streptococcal Pyrogenic Exotoxin B

TF

:   Tissue Factor

TLR

:   Toll-Like Receptor

TM

:   Thrombomodulin

TRPV

:   Transient Receptor Potential Channels Vanilloid Subtype

VCAM

:   Vascular Cell Adhesion Molecule

VEGF

:   Vascular Endothelial Growth Factor

VEGFR

:   Vascular Endothelial Growth Factor Receptor

We would like to thank Hermenegild K. Heuberger for the drawing of the figures.

We thank Enago (<http://www.enago.com>) for the english language review.

Funding {#FPar10}
=======

We would like to express our sincere gratitude for the support given to RAS by the Swiss National Science Foundation grant \#PZ00P3_136639 for the salary of DMH.

Availability of data and materials {#FPar11}
==================================

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Manuscript preparation by DMH and RAS. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar12}
==========================================

Not applicable.

Consent for publication {#FPar13}
=======================

Not applicable.

Competing interests {#FPar14}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar15}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
